Eli Lilly and Company vs Novo Nordisk A/S: Strategic Comparison

This in-depth comparison examines Eli Lilly and Company and Novo Nordisk A/S across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Eli Lilly and Company on its own, evaluating Novo Nordisk A/S, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Eli Lilly and Company and Novo Nordisk A/S is widest.

On the headline numbers, annual revenue is $65.2B (FY2025) for Eli Lilly and Company and ~$47B (FY2025) for Novo Nordisk A/S, while their respective market capitalizations stand at $1.06T and $170.0B. Eli Lilly and Company is headquartered in United States and Novo Nordisk A/S in Denmark, and those different home markets shape how each company competes.

Eli Lilly and Company: Eli Lilly is a 150-year-old Indianapolis pharmaceutical company that has become the world's largest drugmaker by market value. For most of its history it was best known for insulin and Prozac. Since 2022, tirzepatide, a dual GIP/GLP-1 agonist sold as Mounjaro for type 2 diabetes and Zepbound for obesity, has transformed its scale, taking revenue from $28.5 billion in 2022 to $65.2 billion in 2025 and a guided $85-87 billion in 2026. The company is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S: Novo Nordisk is a Danish drugmaker headquartered in Bagsvaerd near Copenhagen. Its products include a large share of the world's insulin, plus semaglutide, the molecule behind Ozempic, Wegovy and Rybelsus. Semaglutide made Novo Europe's most valuable company in 2023-2024. The shares have since fallen more than 70% from their peak as Eli Lilly gained share, and the company replaced its CEO and most of its board in 2025. The company is headquartered in Bagsværd, Denmark.

Eli Lilly and Company and Novo Nordisk A/S pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Eli Lilly and Company and Novo Nordisk A/S.

Eli Lilly and Company business model: Lilly makes money by discovering, developing, manufacturing and selling patent-protected prescription medicines. Revenue comes mainly from product sales to wholesalers, pharmacies and health systems, with net prices set through negotiations with insurers, pharmacy benefit managers and governments; collaboration and royalty income adds a smaller share. Cardiometabolic medicines dominate: Mounjaro ($22.97 billion) and Zepbound ($13.54 billion) together produced about 56% of 2025 revenue. Lilly also sells directly to self-pay patients through LillyDirect, including Zepbound vials and Foundayo tablets, which reduces reliance on traditional pharmacy benefit channels for obesity care.

Novo Nordisk A/S business model: Novo Nordisk sells prescription medicines through two segments. Diabetes and Obesity care is the bulk of sales: GLP-1 drugs (Ozempic, Rybelsus, Wegovy injection, the Wegovy pill launched in the US in January 2026 and Wegovy HD 7.2 mg), plus insulins such as Tresiba and NovoRapid. Rare disease covers haemophilia, growth hormone and other endocrine products. In the US, revenue depends on list prices, rebates to pharmacy benefit managers and government programmes such as 340B and Medicare, and increasingly on self-pay channels where patients buy Wegovy directly at lower prices. The US is the largest market; International Operations covers the rest of the world.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Eli Lilly and Company stack up against those of Novo Nordisk A/S.

Eli Lilly and Company competitive advantage: Lilly's advantage combines a century of diabetes and peptide-hormone expertise with manufacturing scale few rivals can match. Tirzepatide's dual GIP/GLP-1 mechanism produced greater weight loss than semaglutide in the head-to-head SURMOUNT-5 trial, and Foundayo gives Lilly a small-molecule GLP-1 pill that can be taken without food or water restrictions and is easier to mass-produce than peptides. Heavy investment in U.S. and European plants lets Lilly supply volume growth that competitors struggle to match.

Novo Nordisk A/S competitive advantage: Novo Nordisk's edge is a century of peptide and insulin manufacturing know-how, large owned API and fill-finish capacity (including three former Catalent sites bought for $11B in 2024), outcomes data such as SELECT (20% lower risk of major cardiovascular events) and FLOW, and the first approved oral GLP-1 for obesity. Foundation control also lets it invest for the long term without takeover risk.

Future prospects matter as much as current results. The growth strategies below explain how Eli Lilly and Company and Novo Nordisk A/S each plan to expand from here.

Eli Lilly and Company growth strategy: Lilly's growth strategy has three parts: expand incretin supply and indications, add oral and next-generation obesity medicines, and diversify through oncology, immunology, neuroscience and genetic medicine. Foundayo (orforglipron) was approved by the FDA on April 1, 2026 and launched through LillyDirect, telehealth and U.S. retail pharmacies. Retatrutide, a GIP/GLP-1/glucagon triple agonist, is in Phase 3. Lilly continues to build U.S. and European manufacturing capacity and uses acquisitions to add pipeline assets.

Novo Nordisk A/S growth strategy: Under CEO Mike Doustdar the strategy is to cut costs (about 9,000 roles targeted in 2025, with reported headcount down further since), push volume through cheaper self-pay and oral options such as the Wegovy pill, roll out Wegovy 7.2 mg internationally, and rebuild the pipeline through deals such as the Akero Therapeutics acquisition for MASH and in-licensing agreements.

A closer look at the financial trajectory of Eli Lilly and Company and Novo Nordisk A/S rounds out the comparison.

Eli Lilly and Company: Revenue rose from $28.5 billion in 2022 to $45.0 billion in 2024 and $65.2 billion in 2025, while net income nearly doubled to $20.6 billion. Growth accelerated again in 2026: second-quarter revenue rose 48% to $23.0 billion, with Mounjaro at $9.94 billion (up 91%) and Zepbound at $4.93 billion. Lilly raised 2026 revenue guidance to $85-87 billion and non-GAAP EPS guidance to $35.50-36.50. Capital expenditures reached $7.8 billion in 2025 as Lilly expanded production capacity. Eli Lilly and Company is a pharmaceutical titan that has experienced massive growth, commanding a monumental market valuation frequently exceeding $700 billion.

Novo Nordisk A/S: Sales grew from ~$18.5B (DKK 122.0B) in 2019 to ~$47B (DKK 309.1B) in 2025, and net profit rose from ~$5.93B (DKK 39.0B) to ~$15.6B (DKK 102.4B), driven by Ozempic and Wegovy. Growth slowed to 6.4% in reported DKK in 2025 as US prices fell and competition rose. In H1 2026 reported sales were ~$26.6B (DKK 175.3B), inflated by a one-off 340B rebate provision reversal; adjusted sales were ~$22.6B (DKK 148.6B). Q2 2026 adjusted sales rose 7% at constant exchange rates, and management guided full-year 2026 adjusted sales and operating profit growth of 0% to -6% at CER.